Addison's disease Medical Services in China

Addison's disease, also known as primary adrenal insufficiency, is a rare, chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone by the adrenal cortex. This deficiency arises from autoimmune destruction of the adrenal glands in approximately 80–90% of cases in developed countries—where the body’s immune system mistakenly targets and damages adrenal cortical tissue. Other causes include infections (e.g., tuberculosis, HIV-associated mycobacterial or fungal infections), bilateral adrenal hemorrhage, metastatic cancer, genetic disorders (e.g., autoimmune polyglandular syndrome type 1, adrenoleukodystrophy), and surgical removal of the adrenals. The pathogenesis centers on glucocorticoid and mineralocorticoid deficiency: cortisol regulates metabolism, immune response, stress adaptation, and blood pressure; aldosterone maintains sodium-potassium balance and intravascular volume. Without replacement, patients face life-threatening adrenal crises—marked by profound hypotension, hyponatremia, hyperkalemia, hypoglycemia, vomiting, confusion, and shock. Epidemiologically, Addison’s disease affects about 100–140 per million people globally, with an annual incidence of 4–6 new cases per million. It occurs equally across sexes and most commonly presents between ages 30–50, though it can manifest at any age—including childhood in genetic forms. Risk factors include personal or family history of autoimmune diseases (e.g., type 1 diabetes, Hashimoto’s thyroiditis, vitiligo), prior tuberculosis exposure (especially in endemic regions), HIV infection, antiphospholipid syndrome, and use of anticoagulants predisposing to adrenal hemorrhage. Quality of life is significantly impacted: fatigue, orthostatic dizziness, weight loss, gastrointestinal distress, depression, and reduced exercise tolerance are common—even with treatment. Patients require lifelong hormone replacement and vigilant self-management, including stress-dose steroid adjustment during illness or injury. Psychological burden is substantial due to unpredictability of crises, medication adherence demands, and social stigma around chronic invisible illness. Pregnancy requires specialized endocrinology oversight to prevent maternal-fetal complications. Early diagnosis remains challenging due to nonspecific, insidious symptoms—leading to delays averaging 3–6 months from symptom onset to confirmation via morning serum cortisol, ACTH, and ACTH stimulation test. With timely, individualized glucocorticoid (hydrocortisone or prednisone) and mineralocorticoid (fludrocortisone) replacement, life expectancy approaches normal, but mortality remains elevated compared to the general population—primarily due to delayed crisis recognition and suboptimal dosing.

Addison’s disease, or primary adrenal insufficiency, is a chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone due to destruction or dysfunction of the adrenal cortex. The most common cause worldwide is autoimmune adrenalitis, accounting for approximately 80–90% of cases in high-income countries. In this condition, autoreactive T lymphocytes and autoantibodies target adrenal cortical antigens—particularly the enzyme 21-hydroxylase (CYP21A2)—leading to progressive lymphocytic infiltration, fibrosis, and eventual atrophy of the zona fasciculata and zona glomerulosa. Autoimmune Addison’s disease frequently occurs as part of autoimmune polyglandular syndrome type 1 (APS-1), associated with mutations in the AIRE gene, or type 2 (APS-2), which includes coexisting autoimmune thyroid disease, type 1 diabetes mellitus, or celiac disease.

Infectious etiologies remain predominant in resource-limited settings. Tuberculosis (Mycobacterium tuberculosis) is the leading infectious cause globally, responsible for up to 50–70% of cases in endemic regions; it induces granulomatous inflammation, caseous necrosis, and fibrotic replacement of adrenal tissue. Other infections include HIV-associated opportunistic pathogens (e.g., cytomegalovirus, Mycobacterium avium complex, Cryptococcus neoformans, and Histoplasma capsulatum), particularly in advanced immunosuppression; fungal infections such as disseminated histoplasmosis in endemic areas (e.g., Ohio and Mississippi River valleys); and less commonly, syphilis (Treponema pallidum) or severe bacterial sepsis causing bilateral adrenal hemorrhage.

Adrenal hemorrhage—often bilateral—is an acute, potentially life-threatening cause, especially in critically ill patients. Risk factors include septic shock (particularly meningococcemia—Waterhouse-Friderichsen syndrome), anticoagulant therapy, trauma, surgery, coagulopathies (e.g., antiphospholipid syndrome), and underlying malignancy. Metastatic disease (e.g., from lung, breast, or melanoma) may infiltrate and destroy adrenal parenchyma, though bilateral involvement sufficient to cause clinical insufficiency is uncommon without concomitant risk factors.

Genetic causes are rare but clinically significant. Inherited disorders include congenital adrenal hyperplasia (e.g., CYP21A2, CYP11B1, or StAR gene mutations), X-linked adrenoleukodystrophy (ABCD1 gene), familial glucocorticoid deficiency (MC2R or MRAP mutations), and triple A syndrome (AAAS gene). Early-onset Addison’s disease (<25 years) warrants genetic evaluation, especially with neurological, dermatological, or developmental comorbidities.

Environmental and iatrogenic triggers modulate disease expression and decompensation. Chronic glucocorticoid therapy suppresses the hypothalamic-pituitary-adrenal (HPA) axis; abrupt withdrawal can unmask latent adrenal insufficiency or precipitate acute adrenal crisis. While not a cause of primary Addison’s, it is critical to distinguish from secondary insufficiency. Environmental stressors—including severe infection, major surgery, trauma, myocardial infarction, or intense physical exertion—can trigger adrenal crisis in established disease due to inability to mount an appropriate cortisol response. Smoking has been associated with increased risk of autoimmune Addison’s, possibly via molecular mimicry or oxidative stress-induced antigen modification. Vitamin D deficiency and certain viral exposures (e.g., Epstein-Barr virus) have been hypothesized as potential environmental cofactors in autoimmunity, though evidence remains associative.

Risk factors for developing Addison’s disease include female sex (female-to-male ratio ~2:1), age (peak incidence 30–50 years, though pediatric and geriatric cases occur), personal or family history of autoimmune disease (e.g., Hashimoto thyroiditis, Graves’ disease, pernicious anemia, vitiligo), and specific HLA haplotypes—most notably HLA-DRB1*03:01 and HLA-DRB1*04:04—which confer susceptibility to autoimmune adrenalitis. Patients with APS-1 carry biallelic loss-of-function AIRE mutations and present with mucocutaneous candidiasis, hypoparathyroidism, and adrenal failure, typically before age 10. Iatrogenic adrenal suppression from prolonged high-dose corticosteroids does not cause primary adrenal damage but necessitates careful tapering to avoid crisis.

In summary, Addison’s disease arises from heterogeneous etiologies spanning autoimmune, infectious, hemorrhagic, neoplastic, and genetic pathways. Recognition of underlying causes and modifiable risk factors—including infection control in endemic areas, vigilant monitoring during glucocorticoid withdrawal, and screening for associated autoimmune conditions—is essential for timely diagnosis, prevention of adrenal crisis, and personalized long-term management in endocrinology practice.

Addison’s disease, or primary adrenal insufficiency, is a chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone due to autoimmune destruction, infection, hemorrhage, or infiltration of the adrenal cortex. It predominantly affects adults aged 30–50 years, with a slight female predominance, and requires lifelong glucocorticoid (and frequently mineralocorticoid) replacement. Early symptoms are insidious, nonspecific, and frequently misattributed to stress, depression, or chronic fatigue syndrome. Patients commonly report progressive fatigue—often profound and unrelieved by rest—accompanied by generalized weakness, anorexia, unintentional weight loss (typically 5–15% of baseline body weight over months), and low-grade fever. Orthostatic dizziness or presyncope is frequent due to volume depletion and impaired vascular tone; patients may describe lightheadedness upon standing, with documented orthostatic hypotension (a drop in systolic blood pressure ≥20 mmHg or diastolic ≥10 mmHg within 3 minutes of upright posture). Mild nausea and intermittent abdominal discomfort—sometimes mimicking irritable bowel syndrome—are also early features. Hyperpigmentation, though pathognomonic, may be subtle initially; it manifests first in sun-exposed areas, palmar creases, buccal mucosa, gingival margins, and pressure points (e.g., elbows, knees, knuckles), resulting from elevated ACTH and pro-opiomelanocortin (POMC) peptides that stimulate melanocortin-1 receptors. In women, secondary amenorrhea or decreased libido may occur due to concomitant hypothalamic-pituitary dysregulation or reduced adrenal androgen precursors (e.g., DHEA-S). Men rarely present with sexual dysfunction unless coexisting hypogonadism exists.

Typical symptoms emerge as hormonal deficits worsen and reflect both glucocorticoid and mineralocorticoid deficiency. Profound fatigue and debilitating muscle weakness—particularly proximal myopathy affecting ambulation and stair climbing—are hallmark features. Hypotension becomes persistent, not merely orthostatic, with systolic pressures often <90 mmHg and associated tachycardia. Salt craving is highly characteristic and results from aldosterone deficiency-induced renal sodium wasting and consequent intravascular volume contraction. Gastrointestinal manifestations intensify: recurrent nausea, vomiting, abdominal pain (often diffuse and colicky), and diarrhea may dominate the clinical picture, occasionally leading to misdiagnosis as gastroenteritis or inflammatory bowel disease. Hypoglycemia—especially fasting or postprandial—is common due to impaired gluconeogenesis and counter-regulatory hormone deficiency; patients may experience tremulousness, diaphoresis, confusion, or syncope. Mental status changes include irritability, apathy, difficulty concentrating, and depressive symptoms; severe cases may exhibit psychosis or delirium. A distinctive feature is the absence of fever despite systemic inflammation or infection—due to blunted pyrogenic response from cortisol deficiency.

Accompanying symptoms reflect multisystem involvement. Chronic hyponatremia (often <130 mmol/L) and hyperkalemia (typically 5.0–6.5 mmol/L) arise from aldosterone deficiency and inappropriate ADH secretion (SIADH-like state secondary to cortisol lack). Mild eosinophilia and lymphocytosis may be seen on CBC due to loss of cortisol’s suppressive effect on lymphoid tissue. Patients often demonstrate poor wound healing, increased susceptibility to cutaneous fungal infections (e.g., candidiasis), and recurrent respiratory tract infections owing to impaired immune modulation. Decreased axillary and pubic hair in women reflects diminished adrenal androgen synthesis. Some individuals develop vitiligo, alopecia, or pernicious anemia—signs of associated autoimmune polyglandular syndrome type 2 (APS-2), which includes thyroid autoimmunity (Hashimoto’s or Graves’ disease) and type 1 diabetes mellitus.

Complications stem primarily from acute decompensation (adrenal crisis) or chronic undertreatment. Adrenal crisis is a life-threatening emergency precipitated by infection, trauma, surgery, or abrupt glucocorticoid withdrawal. It presents with acute hypotension/shock, severe vomiting and abdominal pain mimicking surgical abdomen, profound weakness, confusion or coma, hypoglycemia, hyponatremia, hyperkalemia, and fever (in contrast to chronic phase). Mortality exceeds 6% even with prompt treatment. Chronic complications include osteoporosis (from prolonged glucocorticoid replacement or untreated cortisol deficiency), cardiovascular morbidity (due to chronic hypotension and electrolyte imbalance), infertility, and impaired quality of life with persistent fatigue and cognitive complaints. Untreated patients face high risk of sudden death from arrhythmias (secondary to hyperkalemia) or septic shock.

Diagnosis hinges on biochemical confirmation of cortisol deficiency and demonstration of adrenal origin. First-line testing is the high-dose (250 µg) cosyntropin (ACTH) stimulation test: peak serum cortisol <18–20 µg/dL (500 nmol/L) at 30 or 60 minutes confirms adrenal insufficiency. Baseline morning cortisol <3 µg/dL strongly suggests deficiency, while >20 µg/dL makes it unlikely. Plasma ACTH is essential to differentiate primary (ACTH >100 pg/mL) from secondary insufficiency (ACTH low/normal). Renin and aldosterone levels assess mineralocorticoid axis: high plasma renin activity (PRA) with low/normal aldosterone confirms mineralocorticoid deficiency. Anti-21-hydroxylase antibodies are positive in >90% of autoimmune Addison’s cases. Imaging—non-contrast CT of adrenals—may reveal small, atrophic glands (autoimmune) or calcifications (tuberculosis), though normal imaging does not exclude disease.

Differential diagnosis must exclude secondary (pituitary) and tertiary (hypothalamic) adrenal insufficiency, where ACTH is low/normal and renin/aldosterone are preserved. Other considerations include critical illness–related corticosteroid insufficiency (CIRCI), which is transient and context-dependent; congenital adrenal hyperplasia (in younger patients); exogenous glucocorticoid suppression (e.g., after prolonged prednisone use); and psychiatric disorders such as major depressive disorder or somatic symptom disorder. Conditions mimicking hyperpigmentation—hemochromatosis, primary biliary cholangitis, or ectopic ACTH syndrome (which shows *high* cortisol and *very high* ACTH but with *hypokalemia* and *alkalosis*, unlike Addison’s)—must be ruled out. Autoimmune thyroid disease and type 1 diabetes require screening given their strong association with APS-2. Finally, chronic kidney disease may cause hyperkalemia and hyponatremia but lacks hyperpigmentation, hypotension, and cortisol deficiency.

Addison’s disease, or primary adrenal insufficiency, is a chronic endocrine disorder characterized by inadequate production of cortisol and often aldosterone due to autoimmune destruction, infection (e.g., tuberculosis), hemorrhage, or genetic causes affecting the adrenal cortex. Management requires lifelong hormone replacement, vigilant monitoring, and patient education to prevent life-threatening adrenal crises. Treatment is exclusively coordinated by the Department of Endocrinology and is fundamentally conservative—no curative surgical or ablative interventions exist for the underlying adrenal failure. However, definitive management of identifiable secondary causes (e.g., resection of an ACTH-secreting pituitary tumor in secondary adrenal insufficiency) may be considered, though this does not apply to classic primary Addison’s.

Conservative treatment forms the cornerstone of care and centers on physiological glucocorticoid and mineralocorticoid replacement. Patients must receive daily hydrocortisone (15–25 mg total, divided into two or three doses—with the largest dose upon waking and a smaller dose at noon; optional low-dose evening dose if needed for fatigue) to mimic the natural diurnal cortisol rhythm. Prednisone or dexamethasone are alternatives but less physiologic due to longer half-lives and lack of circadian alignment; thus, hydrocortisone remains first-line globally and especially preferred in China for its metabolic fidelity and lower risk of Cushingoid side effects with appropriate dosing. Fludrocortisone acetate (0.05–0.2 mg once daily) is added to replace aldosterone, with dosage titrated based on clinical assessment (orthostatic blood pressure, serum potassium, plasma renin activity), and confirmed by absence of postural hypotension and normalization of electrolytes. Sodium chloride supplementation (3–6 g/day) is frequently advised, particularly during summer months or physical exertion, to support intravascular volume and mitigate salt-wasting.

Medication adherence and stress-dosing protocols are non-negotiable components of pharmacotherapy. During intercurrent illness, injury, surgery, or fever, patients must double or triple their usual hydrocortisone dose for 2–3 days—or administer parenteral hydrocortisone (100 mg IV/IM) immediately if vomiting or altered consciousness occurs. All patients must carry a steroid emergency card and wear medical identification. Regular endocrine follow-up every 3–6 months includes assessment of weight, blood pressure (supine and standing), serum electrolytes, fasting glucose, lipid profile, bone mineral density (DEXA scan every 2–5 years), and evaluation for comorbid autoimmune conditions (e.g., thyroiditis, type 1 diabetes). Dose adjustments are guided by symptom control—not biochemical markers alone—as cortisol assays are unreliable for monitoring replacement adequacy.

Surgical treatment has no role in primary adrenal insufficiency itself. Adrenalectomy is contraindicated and would exacerbate hormonal deficiency. However, in rare cases where Addison’s results from metastatic malignancy, bilateral adrenal hemorrhage secondary to anticoagulation, or infiltrative diseases (e.g., lymphoma), surgical intervention may address the precipitating pathology—but only after endocrine stabilization and never as primary therapy for adrenal failure. Similarly, laparoscopic adrenalectomy for incidentalomas or pheochromocytoma is unrelated to Addison’s management and falls outside this indication. Thus, surgical options are strictly limited to managing coexisting or causative conditions—not the adrenal insufficiency per se.

China offers distinct advantages in the longitudinal management of Addison’s disease. First, the national healthcare system enables broad access to generic hydrocortisone and fludrocortisone at highly subsidized costs—critical for lifelong therapy. Second, integrated endocrine centers in tier-1 hospitals (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital) employ standardized, evidence-based protocols aligned with Endocrine Society and Chinese Endocrine Society guidelines, ensuring consistent diagnostic workup (including ACTH stimulation testing, adrenal autoantibodies, and imaging) and therapeutic titration. Third, digital health infrastructure—including AI-assisted medication reminders, tele-endocrinology consultations, and WeChat-linked patient education platforms—enhances adherence and crisis preparedness, particularly in rural regions via tiered referral networks. Fourth, traditional Chinese medicine (TCM) is cautiously integrated as adjunctive supportive care: licensed TCM practitioners may prescribe individualized herbal formulas (e.g., Si Jun Zi Tang derivatives) to ameliorate fatigue or gastrointestinal symptoms *only* under concurrent endocrine supervision—never as steroid substitutes. Rigorous pharmacovigilance ensures herb–drug interaction screening (e.g., St. John’s wort induction of CYP3A4, which accelerates hydrocortisone metabolism).

Recovery and long-term wellness hinge on proactive self-management. Patients should maintain a written action plan detailing stress-dosing instructions, emergency contacts, and nearest hospital with ICU capability. Annual influenza and pneumococcal vaccination are strongly recommended given increased infection susceptibility. Physical activity should be encouraged but gradually intensified; sudden exhaustive exertion without dose adjustment risks crisis. Nutrition counseling emphasizes balanced macronutrients, avoidance of chronic high-sodium intake (to prevent hypertension), and calcium/vitamin D supplementation (1200 mg Ca²⁺/day, 800–2000 IU vitamin D) to counteract glucocorticoid-induced bone loss. Psychological support is integral—depression and anxiety prevalence exceeds 30% in Addison’s cohorts—and cognitive behavioral therapy (CBT) is increasingly available through hospital-based mental health endocrine liaison services in major Chinese cities. Pregnancy requires preconception counseling and trimester-specific hydrocortisone escalation (up to 30 mg/day in third trimester); obstetric-endocrine co-management is standard in tertiary centers. With strict adherence, regular monitoring, and timely crisis response, life expectancy approaches that of the general population, and quality of life is excellent. Ultimately, successful treatment rests not on technological innovation alone, but on the sustained therapeutic alliance between patient, endocrinologist, and multidisciplinary support systems—principles deeply embedded in China’s patient-centered, protocol-driven endocrine care model.